文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

SOX2通过重编程脂质代谢和组蛋白乙酰化格局来驱动食管鳞状细胞癌。

SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.

作者信息

Wang Zhen, Dai Ruofei, Kang Li, Yang Huan, Chen Zhaosu, He Jianzhong, Shu Lei, Zhong Yiting, Zhang Yunfeng, Hua Zhengyi, Huang Yuanyong, Jiang Yuhan, Li Jiwen, Xu Liyan, Lan Fei, Lin Shu-Hai, Wong Jiemin

机构信息

Shanghai Key Laboratory of Regulatory Biology, Fengxian District Central Hospital-ECNU Joint Center of Translational Medicine, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

出版信息

Nat Commun. 2025 Sep 2;16(1):8190. doi: 10.1038/s41467-025-63591-z.


DOI:10.1038/s41467-025-63591-z
PMID:40897722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12405564/
Abstract

SOX2 is a potent oncodriver for various squamous cancers, but the underlying mechanism is largely unknown. Here we uncover a role of SOX2 in promoting global histone acetylation in esophageal squamous cancer cells (ESCCs). Mechanistic studies reveal that SOX2 promotes global histone acetylation in an AKT-independent manner, and does so by promoting histone acetylation at both SOX2 binding and non-SOX2 binding sites, and accounts for the formation of about half of the super-enhancers. Combined metabolic and transcriptional analyses reveal two mechanisms by which SOX2 enhances global histone acetylation: promoting the expression of multiple histone acetyltransferases and reducing acetyl-CoA consuming fatty acid synthesis in part by repressing the expression of ACSL5. Finally, SOX2 expression correlates negatively with ACSL5 and positively with histone acetylation in clinical esophageal squamous tumors. Altogether, our study uncovers a role of SOX2 in reprogramming lipid metabolism and driving histone hyperacetylation and super-enhancer function, providing mechanistic insights of SOX2 acting as a potent oncodriver.

摘要

SOX2是多种鳞状细胞癌的一种强大的致癌驱动因子,但其潜在机制在很大程度上尚不清楚。在此,我们揭示了SOX2在促进食管鳞状癌细胞(ESCC)中整体组蛋白乙酰化方面的作用。机制研究表明,SOX2以不依赖AKT的方式促进整体组蛋白乙酰化,其通过促进SOX2结合位点和非SOX2结合位点的组蛋白乙酰化来实现这一点,并约占超级增强子形成的一半。综合代谢和转录分析揭示了SOX2增强整体组蛋白乙酰化的两种机制:促进多种组蛋白乙酰转移酶的表达,并通过部分抑制ACSL5的表达来减少消耗乙酰辅酶A的脂肪酸合成。最后,在临床食管鳞状肿瘤中,SOX2表达与ACSL5呈负相关,与组蛋白乙酰化呈正相关。总之,我们的研究揭示了SOX2在重编程脂质代谢以及驱动组蛋白高乙酰化和超级增强子功能方面的作用,为SOX2作为一种强大的致癌驱动因子提供了机制性见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/72910ab8a3e5/41467_2025_63591_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/0917abf9664f/41467_2025_63591_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/9d6f83c19d66/41467_2025_63591_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/d4e0b1e2c465/41467_2025_63591_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/100bfdda432d/41467_2025_63591_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/e183a81ef968/41467_2025_63591_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/5e5c8c27c96f/41467_2025_63591_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/72910ab8a3e5/41467_2025_63591_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/0917abf9664f/41467_2025_63591_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/9d6f83c19d66/41467_2025_63591_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/d4e0b1e2c465/41467_2025_63591_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/100bfdda432d/41467_2025_63591_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/e183a81ef968/41467_2025_63591_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/5e5c8c27c96f/41467_2025_63591_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1771/12405564/72910ab8a3e5/41467_2025_63591_Fig7_HTML.jpg

相似文献

[1]
SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.

Nat Commun. 2025-9-2

[2]
WTAP Mediated m6A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma.

Adv Sci (Weinh). 2025-6-5

[3]
EZH2 suppresses IR-induced ferroptosis by forming a co-repressor complex with HIF-1α to inhibit ACSL4: Targeting EZH2 enhances radiosensitivity in KDM6A-deficient esophageal squamous carcinoma.

Cell Death Differ. 2025-2-7

[4]
Acetyl-CoA synthetase regulates histone acetylation and hippocampal memory.

Nature. 2017-6-15

[5]
PYGB targeted by androgen receptor contributes to tumor progression and metabolic reprogramming in esophageal squamous carcinoma.

Cell Signal. 2024-12

[6]
ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation.

Oncogene. 2025-7-1

[7]
An effective two-stage NMBzA-induced rat esophageal tumor model revealing that the FAT-Hippo-YAP1 axis drives the progression of ESCC.

Cancer Lett. 2024-4-28

[8]
YAP as a therapeutic target in esophageal squamous cell carcinoma: insights and strategies.

Ann Med. 2025-12

[9]
FBXO10 inhibits ferroptosis and promotes the progression of esophageal squamous cell carcinoma by post-translational mediation of ACSL4 degradation.

J Mol Histol. 2025-7-5

[10]
Silencing GRHL3 promotes multiple organ distant metastasis of lung squamous cell carcinoma cells by enhancing SOX2 stability via SIRT1.

J Pathol. 2025-3

本文引用的文献

[1]
AKT1 as a therapeutic target for platinum-resistant SOX2 positive ovarian cancer cells.

Sci Rep. 2025-4-29

[2]
Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma.

Bone Res. 2025-2-24

[3]
Protocol for rapidly inducing genome-wide RNA Pol II hyperphosphorylation by selectively disrupting INTAC phosphatase activity.

STAR Protoc. 2023-12-15

[4]
Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer.

J Exp Clin Cancer Res. 2023-5-31

[5]
Bromodomain inhibitors and therapeutic applications.

Curr Opin Chem Biol. 2023-8

[6]
An acetylation-mediated chromatin switch governs H3K4 methylation read-write capability.

Elife. 2023-5-19

[7]
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.

Molecules. 2023-3-29

[8]
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.

Cancer Cell. 2023-1-9

[9]
Squamous cell lung cancer: Current landscape and future therapeutic options.

Cancer Cell. 2022-11-14

[10]
Generation of knock-in degron tags for endogenous proteins in mice using the dTAG system.

STAR Protoc. 2022-9-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索